Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Nivolumab with cisplatin and radiotherapy improved 3-year disease-free survival to 63.1% versus 52.5% in high-risk head and neck cancer patients. The trial enrolled 680 patients, with Opdivo ...

A new report has laid bare how head and neck cancers have "persistently poor" survival rates in our region.

Head and neck cancer (HNC) represents a significant global health challenge, characterized by aggressive local invasion, frequent recurrence, and poor survival rates. Beyond its physical burden, HNC ...

Enfortumab vedotin and pembrolizumab showed a 39% overall response rate in recurrent/metastatic HNSCC with PD-L1 CPS ≥1. The trial reported a 9.8% complete response rate and a 29.3% partial response ...

The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity ...

Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to ...

RARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational ...

While mortality rates are at record lows, experts warn that certain cancers are increasing—especially among younger adults.